Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Citius OncologyCTOR -3.07%10 Days Sales Outstanding is 53.90 as of Jun. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 946 Drug Manufacturers companies, Citius Oncology ranks worse than 71.99% on this metric.
Citius Oncology (NAS:CTOR) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Citius Oncology Days Sales Outstanding Related Terms
Citius Oncology Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Citius Oncology's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTOR vs ZYBT, INCR, TLPH: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Oncology Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Citius Oncology's Days Sales Outstanding falls into.
Citius Oncology Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Oncology (CTOR) has a Days Sales Outstanding of 53.90 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Citius Oncology and its competitors. According to the industry distribution chart, Citius Oncology ranks #681 out of 946 companies in the Drug Manufacturers industry, placing it in the top 72%.
Is Citius Oncology's Days Sales Outstanding too high?
Citius Oncology's current Days Sales Outstanding is 53.90. The Drug Manufacturers industry median Days Sales Outstanding is 71.89. Citius Oncology's value of 53.90 is 25% below this industry median. Based on the distribution chart, Citius Oncology ranks #681 out of 946 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Days Sales Outstanding compare to ZYBT and INCR?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #681 out of 946 companies for Days Sales Outstanding. This places Citius Oncology in the lower half of its industry. The industry median Days Sales Outstanding is 71.89. Citius Oncology's value of 53.90 is 25% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.89, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Oncology's current Days Sales Outstanding of 53.90 is 25% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current Days Sales Outstanding is 53.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Days Sales Outstanding of 53.90. The current Days Sales Outstanding is 53.90 and 25% below the Drug Manufacturers industry median of 71.89. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Days Sales Outstanding is 53.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 
